• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

  2. Research and Markets: Medullary Thyroid Cancer Pipeline Review, H1 2015

    Research and Markets: Medullary Thyroid Cancer Pipeline Review, H1 2015

  3. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.